Abstract
Bifactor models are a promising strategy to parse general from specific aspects of psychopathology in youth. Currently, there are multiple configurations of bifactor models originating from different theoretical and empirical perspectives. Our aim is to identify and test the reliability, validity, measurement invariance, and the correlation of different bifactor models of psychopathology using the Child Behavior Checklist (CBCL). We used data from the Reproducible Brain Charts (RBC) initiative (N=7,011, ages 5 to 22 years, 40.2% females). Factor models were tested using the baseline data. To address our aim, we a) mapped the published bifactor models using the CBCL; b) tested their global model fit; c) calculated model-based reliability indices. d) tested associations with symptoms’ impact in everyday life; e) tested measurement invariance across many characteristics and f) analyzed the observed factor correlation across the models. We found 11 bifactor models ranging from 39 to 116 items. Their global model fit was broadly similar. Factor determinacy and H index were acceptable for the p-factors, internalizing, externalizing and somatic specific factors in most models. However, only p- and attention factors were predictors of symptoms’ impact in all models. Models were broadly invariant across different characteristics. P-factors were highly correlated across models (r = 0.88 to 0.99). Homotypic specific factors were also highly correlated. Regardless of item selection and strategy to compose CBCL bifactor models, results suggest that they all assess very similar constructs. Our results provide support for the robustness of the bifactor of psychopathology and distinct study characteristics.
General Scientific Summaries This study supports the notion that models of psychopathology that separate what is general from what is specific in mental health problems have little impact from item selection and types of specific dimensions. The general dimensions are highly correlated among different models, valid to predict symptom impact in daily life and are not influenced by demographic and clinical characteristics, time and information.
Competing Interest Statement
Luis Augusto Rohde has received grant or research support from, served as a consultant to, and served on the speakers' bureau of Ache, Bial, Medice, Novartis/Sandoz, Pfizer/Upjohn, and Shire/Takeda in the last three years. The ADHD and Juvenile Bipolar Disorder Outpatient Programs chaired by Dr Rohde have received unrestricted educational and research support from the following pharmaceutical companies in the last three years: Novartis/Sandoz and Shire/Takeda. Dr Rohde has received authorship royalties from Oxford Press and ArtMed. Other authors declare no conflicts of interest.
Funding Statement
This work was supported by the following grants from the United States National Institutes of Health: R01MH120482-01. https://grantome.com/grant/NIH/R01-MH120482-01
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The exemption was authorized by the UPenn IRB in 12 June 2019. The IRB has determined that the proposal meets eligibility criteria for IRB review exemption authorized by 45 CFR 46.104, category #4 IRB Protocol number: 833438
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Dr. Hoffmann have full access the phenotypic harmonized data set used in the study, as well as analysis code, and takes responsibility for the integrity of the data and the accuracy of the data analysis. Data is available upon request at the moment. However, the end product of the RBC project is to release a complete harmonized data set to the scientific community, combining phenotypic with neuroimaging data. Metadata, R and Mplus code to process raw variables used in this study can be found at https://osf.io/uwy5n/
